Primary bone lymphoma the university of miami experience

Alvaro Alencar, David Pitcher, Gerald Byrne, Izidore Lossos

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Primary bone lymphoma (PBL) is a rare disease. There has been paucity of studies addressing its therapy and prognosis. We retrospectively examined PBL cases seen at the University of Miami from June 2000 to August 2007 to describe our single institution experience and review the literature. Fifty-three patients were identified with a median age of 52 (18-87) and a median follow-up of 40 months (0-106). The most common histologic type was diffuse large B-cell lymphoma (83%). Fortyone patients (77%) presented with localized disease and 48 were treated at our institution. Forty-six patients underwent chemotherapy (40 patients) and/or radiation (36 patients). Forty-four patients achieved a complete response and all patients were alive at last follow-up. The progression-free survival (PFS) was 83% at 4 years. No difference in PFS was observed between patients treated with chemotherapy or combined chemotherapy plus radiation. There was a trend toward improvement in PFS (p=0.062) of patients with DLBCL treated with rituximab plus chemotherapy. Our single institutional experience demonstrates that the outcome of patients with PBL is excellent. Although the current data support the use of combined modality treatment for localized PBL, randomized controlled trials are needed especially now, when rituximab is routinely added to chemotherapy regimens.

Original languageEnglish
Pages (from-to)39-49
Number of pages11
JournalLeukemia and Lymphoma
Volume51
Issue number1
DOIs
StatePublished - Jan 1 2010

Fingerprint

Lymphoma
Bone and Bones
Drug Therapy
Disease-Free Survival
Radiation
Lymphoma, Large B-Cell, Diffuse
Rare Diseases
Randomized Controlled Trials
Therapeutics

Keywords

  • Bone lymphoma
  • Combination chemo-radiation
  • Rituximab

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Primary bone lymphoma the university of miami experience. / Alencar, Alvaro; Pitcher, David; Byrne, Gerald; Lossos, Izidore.

In: Leukemia and Lymphoma, Vol. 51, No. 1, 01.01.2010, p. 39-49.

Research output: Contribution to journalArticle

Alencar, Alvaro ; Pitcher, David ; Byrne, Gerald ; Lossos, Izidore. / Primary bone lymphoma the university of miami experience. In: Leukemia and Lymphoma. 2010 ; Vol. 51, No. 1. pp. 39-49.
@article{f4c5aadbd3484edd8db72582cdc28f2d,
title = "Primary bone lymphoma the university of miami experience",
abstract = "Primary bone lymphoma (PBL) is a rare disease. There has been paucity of studies addressing its therapy and prognosis. We retrospectively examined PBL cases seen at the University of Miami from June 2000 to August 2007 to describe our single institution experience and review the literature. Fifty-three patients were identified with a median age of 52 (18-87) and a median follow-up of 40 months (0-106). The most common histologic type was diffuse large B-cell lymphoma (83{\%}). Fortyone patients (77{\%}) presented with localized disease and 48 were treated at our institution. Forty-six patients underwent chemotherapy (40 patients) and/or radiation (36 patients). Forty-four patients achieved a complete response and all patients were alive at last follow-up. The progression-free survival (PFS) was 83{\%} at 4 years. No difference in PFS was observed between patients treated with chemotherapy or combined chemotherapy plus radiation. There was a trend toward improvement in PFS (p=0.062) of patients with DLBCL treated with rituximab plus chemotherapy. Our single institutional experience demonstrates that the outcome of patients with PBL is excellent. Although the current data support the use of combined modality treatment for localized PBL, randomized controlled trials are needed especially now, when rituximab is routinely added to chemotherapy regimens.",
keywords = "Bone lymphoma, Combination chemo-radiation, Rituximab",
author = "Alvaro Alencar and David Pitcher and Gerald Byrne and Izidore Lossos",
year = "2010",
month = "1",
day = "1",
doi = "10.3109/10428190903308007",
language = "English",
volume = "51",
pages = "39--49",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Primary bone lymphoma the university of miami experience

AU - Alencar, Alvaro

AU - Pitcher, David

AU - Byrne, Gerald

AU - Lossos, Izidore

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Primary bone lymphoma (PBL) is a rare disease. There has been paucity of studies addressing its therapy and prognosis. We retrospectively examined PBL cases seen at the University of Miami from June 2000 to August 2007 to describe our single institution experience and review the literature. Fifty-three patients were identified with a median age of 52 (18-87) and a median follow-up of 40 months (0-106). The most common histologic type was diffuse large B-cell lymphoma (83%). Fortyone patients (77%) presented with localized disease and 48 were treated at our institution. Forty-six patients underwent chemotherapy (40 patients) and/or radiation (36 patients). Forty-four patients achieved a complete response and all patients were alive at last follow-up. The progression-free survival (PFS) was 83% at 4 years. No difference in PFS was observed between patients treated with chemotherapy or combined chemotherapy plus radiation. There was a trend toward improvement in PFS (p=0.062) of patients with DLBCL treated with rituximab plus chemotherapy. Our single institutional experience demonstrates that the outcome of patients with PBL is excellent. Although the current data support the use of combined modality treatment for localized PBL, randomized controlled trials are needed especially now, when rituximab is routinely added to chemotherapy regimens.

AB - Primary bone lymphoma (PBL) is a rare disease. There has been paucity of studies addressing its therapy and prognosis. We retrospectively examined PBL cases seen at the University of Miami from June 2000 to August 2007 to describe our single institution experience and review the literature. Fifty-three patients were identified with a median age of 52 (18-87) and a median follow-up of 40 months (0-106). The most common histologic type was diffuse large B-cell lymphoma (83%). Fortyone patients (77%) presented with localized disease and 48 were treated at our institution. Forty-six patients underwent chemotherapy (40 patients) and/or radiation (36 patients). Forty-four patients achieved a complete response and all patients were alive at last follow-up. The progression-free survival (PFS) was 83% at 4 years. No difference in PFS was observed between patients treated with chemotherapy or combined chemotherapy plus radiation. There was a trend toward improvement in PFS (p=0.062) of patients with DLBCL treated with rituximab plus chemotherapy. Our single institutional experience demonstrates that the outcome of patients with PBL is excellent. Although the current data support the use of combined modality treatment for localized PBL, randomized controlled trials are needed especially now, when rituximab is routinely added to chemotherapy regimens.

KW - Bone lymphoma

KW - Combination chemo-radiation

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=74949094509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74949094509&partnerID=8YFLogxK

U2 - 10.3109/10428190903308007

DO - 10.3109/10428190903308007

M3 - Article

VL - 51

SP - 39

EP - 49

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 1

ER -